Clinical trials: multiple sclerosis
Multiple Sclerosis, Relapsing-Remitting
Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis
The purpose of this study is to determine if a higher dose of study drug is more effective in preventing relapses in patients with Multiple Sclerosis.
- Trial name
- NCT00235989
- Testing
- Interferon beta 1b (Betaseron, BAY86-5046)
- Where
- 17 sites in United States
- Volunteers
- 63 people
- Sponsor
- Bayer
Multiple Sclerosis, Relapsing-Remitting
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
The primary objective of the study is to evaluate the long-term safety of BG00012 in subjects who completed Study 109MS202 (NCT02410200).
- Trial name
- NCT02555215
- Testing
- dimethyl fumarate
- Where
- 12 sites in United States, Belgium and 8 more
- Volunteers
- 20 people
- Sponsor
- Biogen
Relapsing-remitting Multiple Sclerosis
COMparison Between All immunoTherapies for Multiple Sclerosis.
The overarching goal of this study is to determine whether rituximab (RTX) offers effectiveness and safety advantages over other commonly used approved Disease-Modifying Drugs (DMT) in the largest real-world population-based…
- Trial name
- COMBAT-MS (NCT03193866)
- Testing
- Rituximab
- Where
- Sweden
- Volunteers
- 3,526 people
- Sponsor
- Karolinska Institutet
Multiple Sclerosis
A Study to Test the Use of Duloxetine for Pain in MS
Many patients with Multiple Sclerosis experience pain that is caused by the effects of MS on the nervous system. The purpose of this study is to see if an investigational drug (Duloxetine) will reduce pain in subjects with MS.
- Trial name
- NCT00457730
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Brown, Theodore R., M.D., MPH
Relapsing-Remitting Multiple Sclerosis
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. To determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in…
- Trial name
- DEFINE (NCT00420212)
- Testing
- BG00012
- Where
- 159 sites in United States, Australia and 27 more
- Volunteers
- 1,234 people
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
The primary objective of the study is to evaluate the safety and tolerability of BG00012 (dimethyl fumarate) administered in combination with interferon b (IFNß) or glatiramer acetate (GA) in participants with relapsing-remitting…
- Trial name
- EXPLORE (NCT01156311)
- Testing
- dimethyl fumarate
- Where
- 16 sites in United States
- Volunteers
- 108 people
- Sponsor
- Biogen
Multiple Sclerosis
Effects of Training on Central Auditory Function in Multiple Sclerosis
The purpose of this study is to characterize the central auditory processing (CAP) deficits that result from multiple sclerosis (MS).
- Trial name
- NCT01023074
- Testing
- Auditory training, MS: Control Activity
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Relapsing Multiple Sclerosis
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)
Primary Objective: To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS Secondary…
- Trial name
- GEMINI 1 (NCT04410978)
- Testing
- Tolebrutinib, Teriflunomide
- Where
- 179 sites in United States, Austria and 22 more
- Volunteers
- 974 people
- Sponsor
- Sanofi
Relapsing Forms of Multiple Sclerosis
A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)
The primary objectives of this study are to determine the safety and tolerability of DRF administered for up to 24 weeks in adult East Asian participants with RMS (Part 1) and to determine the safety and tolerability of DRF…
- Trial name
- NCT05083923
- Testing
- Diroximel fumarate
- Where
- 52 sites in China, Japan
- Volunteers
- 136 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis (RRMS)
A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
The primary objective of the study is to evaluate the evolution of walking capacity as measured by the timed 100-meter walk test (T100T), timed 25-foot walk test (T25FW), maximum walking distance (MWD), and Expanded Disability…
- Trial name
- TIMER (NCT00871780)
- Testing
- BG00002 (natalizumab)
- Where
- 15 sites in Belgium, Mexico and 4 more
- Volunteers
- 224 people
- Sponsor
- Biogen
Fatigue in Multiple Sclerosis
Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis
Randomized, placebo-controlled, crossover, 4-sequence, 4-period, double-blind (participants and investigators), multicenter trial of 3 commonly used medications for treatment of MS-related fatigue (amantadine, modafinil…
- Trial name
- TRIUMPHANT-MS (NCT03185065)
- Testing
- Amantadine, Modafinil, Methylphenidate
- Where
- 2 sites in United States
- Volunteers
- 141 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis, Colitis, Ulcerative
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants
This is a first time in human study designed to assess the safety, tolerability, pharmacokinetics and PD of GSK3888130B over a range of dose levels in healthy participants.
- Trial name
- NCT05131971
- Testing
- GSK3888130B
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Secondary-progressive Multiple Sclerosis
Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis
To assess the efficacy of Mayzent on microglia pathology in patients with active SPMS, as compared to the active control group of MS patients treated with the Ocrevus, as measured by changes in microglial activation in the…
- Trial name
- NCT04925557
- Testing
- Mayzent, Ocrevus
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- State University of New York at Buffalo
Multiple Sclerosis
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
The purpose of the study is to show that individuals treated with Fampridine-SR tablets are significantly more likely to have consistent improvements in their walking than those treated with placebo tablets.
- Trial name
- NCT00483652
- Testing
- Fampridine-SR
- Where
- 40 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Acorda Therapeutics
Multiple Sclerosis
Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis
This study evaluated the safety, tolerability and effect on MRI lesion parameters of FTY720 in patients with relapsing multiple sclerosis.
- Trial name
- NCT00333138
- Testing
- FTY720
- Where
- 26 sites in Canada, Denmark and 9 more
- Volunteers
- 281 people
- Sponsor
- Novartis
Multiple Sclerosis
A Pilot Trial of Remotely-Supervised Transcranial Direct Current Stimulation (RS-tDCS) to Enhance Motor Learning in Progressive Multiple Sclerosis (MS)
This is a randomized, double-blind pilot clinical trial to test a novel treatment approach to rehabilitate fine motor function in individuals living with progressive multiple sclerosis (MS) using anodal transcranial direct…
- Trial name
- NCT03499314
- Testing
- Active RS-tDCS +At-Home Manual Dexterity Training, Manual dexterity training
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- NYU Langone Health
Relapsing Remitting Multiple Sclerosis
Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change
The purpose of this study is to evaluate the change in patient-reported treatment satisfaction after 6 months of treatment with fingolimod 0.5mg/day vs.
- Trial name
- EPOC (NCT01317004)
- Testing
- Fingolimod, Standard MS DMT
- Where
- 17 sites in Italy
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Cognitive-behavior Therapy for MS-Related Chronic Pain
The purpose of this study is to evaluate the efficacy of a brief psychological intervention, cognitive-behavior therapy, for the management of persistent pain associated with Multiple Sclerosis.
- Trial name
- NCT00323271
- Testing
- Cognitive-behavior therapy, Interventional
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- US Department of Veterans Affairs
Multiple Sclerosis
Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis
Multiple sclerosis is the most common inflammatory disease of the central nervous system and a common cause of disability in young adults.
- Trial name
- NCT04767698
- Testing
- Belimumab, Short-course Ocrelizumab, Continued Ocrelizumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis
A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly
The aim of this multicentre, randomised, double-blind, placebo-controlled study is to evaluate the efficacy and safety of supplementary treatment with cholecalciferol (vitamin D3) in subjects with relapsing multiple sclerosis (R…
- Trial name
- CHOLINE (NCT01198132)
- Testing
- Cholecalciferol (Vitamin D3), Rebif
- Where
- France
- Volunteers
- 129 people
- Sponsor
- Merck KGaA, Darmstadt, Germany